Literature DB >> 3741727

Renal failure does not impair the metabolism of morphine.

D F Woolner, D Winter, T J Frendin, E J Begg, K L Lynn, G J Wright.   

Abstract

The pharmacokinetics of morphine were measured using gas chromatography-mass spectrometry (GCMS) with specific ion monitoring after the intramuscular administration of papaveretum to four patients with renal failure (one anephric) and three normals. The apparent t1/2 of absorption and t1/2 of elimination were significantly shorter in the patients with renal failure (P less than 0.05). Morphine glucuronides are eliminated slowly in these patients as expected. Renal failure does not impair the elimination of morphine.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3741727      PMCID： PMC1401094          DOI： 10.1111/j.1365-2125.1986.tb02880.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  13 in total

1.  Mass fragmentography of morphine and 6-monoacetylmorphine in blood with a stable isotope internal standard.

Authors:  W O Ebbighausen; J H Mowat; H Stearns; P Vestergaard
Journal:  Biomed Mass Spectrom       Date:  1974-10

2.  Be aware of renal function when prescribing morphine.

Authors:  H McQuay; A Moore
Journal:  Lancet       Date:  1984-08-04       Impact factor: 79.321

3.  Morphine metabolism: does the renal hypothesis hold water?

Authors:  G W Hanks; G W Aherne
Journal:  Lancet       Date:  1985-01-26       Impact factor: 79.321

4.  Kinetics of morphine in patients with renal failure.

Authors:  J Säwe; J O Svensson; I Odar-Cederlöf
Journal:  Lancet       Date:  1985-07-27       Impact factor: 79.321

5.  Morphine radioimmunoassay specificity before and after extraction of plasma and cerebrospinal fluid.

Authors:  P Y Grabinski; R F Kaiko; T D Walsh; K M Foley; R W Houde
Journal:  J Pharm Sci       Date:  1983-01       Impact factor: 3.534

6.  Sensitive and specific morphine radioimmunoassay with iodine label: pharmacokinetics of morphine in man after intravenous administration.

Authors:  R A Moore; D Baldwin; M C Allen; P J Watson; R E Bullingham; H J McQuay
Journal:  Ann Clin Biochem       Date:  1984-07       Impact factor: 2.057

7.  A multiple-scan high resolution mass spectrometer data system for the analysis of mixtures: the analysis of morphine in liver.

Authors:  H K Lee; P A Gnad; P R Trebilco; G J Wright; L K Pannell
Journal:  Biomed Mass Spectrom       Date:  1980-10

8.  Urinary excretion of morphine and its metabolites in morphine-dependent subjects.

Authors:  S Y Yeh
Journal:  J Pharmacol Exp Ther       Date:  1975-01       Impact factor: 4.030

9.  Kinetics of intravenous and intramuscular morphine.

Authors:  D R Stanski; D J Greenblatt; E Lowenstein
Journal:  Clin Pharmacol Ther       Date:  1978-07       Impact factor: 6.875

10.  Cardiovascular changes in chronic hemodialysis patients.

Authors:  H Ikram; K L Lynn; R R Bailey; P J Little
Journal:  Kidney Int       Date:  1983-09       Impact factor: 10.612
View more
  9 in total

Review 1.  Enterohepatic circulation of opioid drugs. Is it clinically relevant in the treatment of cancer patients?

Authors:  G W Hanks; P J Wand
Journal:  Clin Pharmacokinet       Date:  1989-08       Impact factor: 6.447

2.  Morphine intoxication in renal failure; the role of morphine-6-glucuronide.

Authors:  R Osborne; S Joel; M Slevin
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-25

3.  Long lasting respiratory depression induced by morphine-6-glucuronide?

Authors:  J Hasselström; U Berg; A Löfgren; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1989-04       Impact factor: 4.335

Review 4.  Pharmacokinetics of opioids in renal dysfunction.

Authors:  G Davies; C Kingswood; M Street
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

5.  The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients.

Authors:  R W Milne; R L Nation; A A Somogyi; F Bochner; W M Griggs
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

6.  Pharmacogenomics of codeine, morphine, and morphine-6-glucuronide: model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 inhibition.

Authors:  Thomas Eissing; Jörg Lippert; Stefan Willmann
Journal:  Mol Diagn Ther       Date:  2012-02-01       Impact factor: 4.074

7.  Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration.

Authors:  G M Peterson; C T Randall; J Paterson
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

8.  Influence of renal function on the elimination of morphine and morphine glucuronides.

Authors:  J Wolff; D Bigler; C B Christensen; S N Rasmussen; H B Andersen; K H Tønnesen
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

9.  Morphine: pharmacokinetics and clinical practice.

Authors:  P J Hoskin; G W Hanks
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.